Immunogenicity and Safety Study of GSK Biologicals' HPV Vaccine (GSK 580299) in Healthy Adult Chinese Female Subjects.

Trial Profile

Immunogenicity and Safety Study of GSK Biologicals' HPV Vaccine (GSK 580299) in Healthy Adult Chinese Female Subjects.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2016

At a glance

  • Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; Hepatitis B vaccine recombinant
  • Indications Cervical cancer; Hepatitis B; Human papillomavirus infections
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 04 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Apr 2012 Actual patient number is 1212 as reported by ClinicalTrials.gov.
    • 10 Feb 2012 Planned end date changed from 1 Sep 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top